CPhI Online

- Market News

World’s leading biobanks join a global network to advance personalized healthcare research

6 Apr 2020

The platform enables collaboration between pharmaceutical institutions, healthcare and academic researchers to generate valuable insights and advance medical research.

BC Platforms, the provider of a powerful data and technology platform for personalized healthcare, has added three new leading biobanks to its Global Data Partner Network, BCRQUEST.com: Generation Scotland (UK), Bialystok Biobank (Poland) and Biobank Graz (Austria).

The BCRQUEST.com platform enables researchers to efficiently access harmonized data while strictly adhering to global and local data privacy and security regulations.

The platform and its supporting framework facilitate collaboration between pharmaceutical institutions, healthcare and academic researchers to generate valuable insights and advance medical research.

The addition of these three new, high-quality biobanks brings the BCRQUEST.com network to almost 3.5 million consented patient healthcare records from nearly 10 countries in North America and Europe.

Bialystok Biobank focuses on clinical samples for cancer and specifically on new biomarkers for early diagnosis, as well as personalized therapy of cancer-based on genetic-molecular disorders.

Biobank Graz is one of the biggest biobanks in the world with 20 million tissue, blood and DNA samples from more than 1.2 million patients.

Generation Scotland is a population-based cohort designed to study the genetic and environmental determinants of health.

Dr Christian Gülly, COO, Biobank Graz, Medical University of Graz, Austria, commented: “We are excited to be collaborating with BC Platforms to securely share our data for the benefit of patients without compromising any privacy issues. We have been impressed by the BCRQUEST.com platform and its ability to analyse, integrate and share data in a secure manner and in line with the European General Data Protection Regulation (GDPR) to support researchers in developing personalized medicines.”

Given BC Platforms' strong focus on genetic and clinical data, Tero Silvola, CEO of BC Platforms described their growing network as a "unique" and "invaluable asset" for researchers and industry. Speaking of the new addition, he said: "This will progress the development of personalized healthcare for the benefit of patients, healthcare systems and research.”

Read More

Related Content